Inflammation Research 2013-03-01

Flupirtine, a re-discovered drug, revisited.

Istvan Szelenyi

Index: Inflamm. Res. 62(3) , 251-8, (2013)

Full Text: HTML

Abstract

Flupirtine was developed long before K(V)7 (KCNQ) channels were known. However, it was clear from the beginning that flupirtine is neither an opioid nor a nonsteroidal anti-inflammatory analgesic. Its unique muscle relaxing activity was discovered by serendipity. In the meantime, broad and intensive research has resulted in a partial clarification of its mode of action. Flupirtine is the first therapeutically used K(V)7 channel activator with additional GABA(A)ergic mechanisms and thus the first representative of a novel class of analgesics. The presently accepted main mode of its action, potassium K(V)7 (KCNQ) channel activation, opens a series of further therapeutic possibilities. One of them has now been realized: its back-up compound, the bioisostere retigabine, has been approved for the treatment of epilepsy.

Related Compounds

  • Flupirtine maleate

Related Articles:

Role of Kv7 channels in responses of the pulmonary circulation to hypoxia.

2015-01-01

[Am. J. Physiol. Lung Cell. Mol. Physiol. 308(1) , L48-57, (2015)]

M channel enhancers and physiological M channel block.

2012-02-15

[J. Physiol. 590(Pt 4) , 793-807, (2012)]

M-type potassium channels modulate Schaffer collateral-CA1 glutamatergic synaptic transmission.

2012-08-15

[J. Physiol. 590(Pt 16) , 3953-64, (2012)]

Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data.

2011-10-01

[J. Inherit. Metab. Dis. 34(5) , 1075-81, (2011)]

Protective effect of the KCNQ activator flupirtine on a model of repetitive febrile seizures

2011-11-01

[Epilepsy Res. 97(1-2) , 64-72, (2011)]

More Articles...